{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=30",
    "query": {
      "condition": "Advanced Stage Solid Tumors",
      "page": 30
    },
    "page_size": 10
  },
  "pagination": {
    "page": 30,
    "page_size": 10,
    "total_count": 3080,
    "total_pages": 308,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=31&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=29&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-16T21:39:43.419Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04087018",
      "title": "Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "zimberelimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arcus Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2019-09-24",
      "completion_date": "2024-06-17",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-11-16T21:39:43.419Z",
      "location_count": 9,
      "location_summary": "Riverside, California • Roseville, California • Newark, Delaware + 5 more",
      "locations": [
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Gaithersburg",
          "state": "Maryland"
        },
        {
          "city": "Saint Louis Park",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04087018"
    },
    {
      "nct_id": "NCT06171178",
      "title": "A Study of ASP1012 in Adults With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "ASP1012",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2024-05-15",
      "completion_date": "2025-09-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-11-16T21:39:43.419Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06171178"
    },
    {
      "nct_id": "NCT05838768",
      "title": "Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers"
      ],
      "interventions": [
        {
          "name": "HRO761",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 123,
      "start_date": "2023-06-27",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-11-16T21:39:43.419Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05838768"
    },
    {
      "nct_id": "NCT04863248",
      "title": "Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Non-Small Cell Lung Cancer",
        "NSCLC",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Trilaciclib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "G1 Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2021-04-30",
      "completion_date": "2022-02-02",
      "has_results": true,
      "last_update_posted_date": "2023-04-14",
      "last_synced_at": "2026-11-16T21:39:43.419Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Rancho Mirage, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04863248"
    },
    {
      "nct_id": "NCT03037385",
      "title": "Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "RET-altered Non Small Cell Lung Cancer",
        "Medullary Thyroid Cancer",
        "RET-altered Papillary Thyroid Cancer",
        "RET-altered Colon Cancer",
        "RET-altered Solid Tumors",
        "Lung Neoplasm",
        "Carcinoma, Non-Small-Cell Lung",
        "Thyroid Diseases",
        "Thyroid Neoplasm",
        "Thyroid Cancer, Papillary",
        "Carcinoma, Neuroendocrine",
        "Respiratory Tract Neoplasms",
        "Thoracic Neoplasms",
        "Neoplasms by Site",
        "Neoplasms",
        "Lung Diseases",
        "Respiratory Tract Disease",
        "Carcinoma, Bronchogenic",
        "Bronchial Neoplasms",
        "Endocrine System Diseases",
        "Endocrine Gland Neoplasm",
        "Head and Neck Neoplasms",
        "Adenocarcinoma, Papillary",
        "Adenocarcinoma",
        "Carcinoma",
        "Neoplasms, Glandular and Epithelial",
        "Neoplasms by Histologic Type",
        "Neuroendocrine Tumors",
        "Neuroectodermal Tumors",
        "Neoplasms, Germ Cell and Embryonal",
        "Neoplasms, Nerve Tissue",
        "Colonic Neoplasms",
        "Colorectal Neoplasms",
        "Intestinal Neoplasms",
        "Gastrointestinal Neoplasms",
        "Digestive System Neoplasm",
        "Digestive System Disease",
        "Gastrointestinal Disease",
        "Colonic Diseases",
        "Intestinal Disease"
      ],
      "interventions": [
        {
          "name": "pralsetinib (BLU-667)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 590,
      "start_date": "2017-03-17",
      "completion_date": "2024-03-21",
      "has_results": true,
      "last_update_posted_date": "2025-05-31",
      "last_synced_at": "2026-11-16T21:39:43.419Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Orange, California • Aurora, Colorado + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03037385"
    },
    {
      "nct_id": "NCT05388435",
      "title": "Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "SKL27969",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SK Life Science, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2022-09-12",
      "completion_date": "2024-03-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-04",
      "last_synced_at": "2026-11-16T21:39:43.419Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Grand Rapids, Michigan • Huntersville, North Carolina + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05388435"
    },
    {
      "nct_id": "NCT06697197",
      "title": "A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "BMS-986482",
          "type": "DRUG"
        },
        {
          "name": "Pumitamig",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 286,
      "start_date": "2025-02-17",
      "completion_date": "2029-01-05",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-11-16T21:39:43.419Z",
      "location_count": 7,
      "location_summary": "Irvine, California • Los Angeles, California • Aurora, Colorado + 4 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06697197"
    },
    {
      "nct_id": "NCT00550017",
      "title": "A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Epofolate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2007-12",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2015-10-12",
      "last_synced_at": "2026-11-16T21:39:43.419Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00550017"
    },
    {
      "nct_id": "NCT01362374",
      "title": "Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "5-FU",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Ipatasertib",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2011-07-11",
      "completion_date": "2020-10-16",
      "has_results": false,
      "last_update_posted_date": "2022-01-12",
      "last_synced_at": "2026-11-16T21:39:43.419Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01362374"
    },
    {
      "nct_id": "NCT02335918",
      "title": "A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck (SCCHN)",
        "Ovarian Carcinoma-Enrollment Completed",
        "Colorectal Cancer (CRC)-Enrollment Completed",
        "Renal Cell Carcinoma (RCC) (Phase ll Only)",
        "Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed"
      ],
      "interventions": [
        {
          "name": "Combination of varlilumab and nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2015-01",
      "completion_date": "2018-12-12",
      "has_results": false,
      "last_update_posted_date": "2019-12-09",
      "last_synced_at": "2026-11-16T21:39:43.419Z",
      "location_count": 19,
      "location_summary": "Tucson, Arizona • Palo Alto, California • San Francisco, California + 13 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02335918"
    }
  ]
}